Using MALDI-TOF mass spectrometry in peripheral blood for the follow up of newly diagnosed multiple myeloma patients treated with daratumumab-based combination therapy

BACKGROUND: Daratumumab-based combination therapies have shown high rates of complete response (CR) and minimal residual disease negativity in patients with multiple myeloma. However, daratumumab, an IgGκ monoclonal antibody, interferes with electrophoretic techniques making it difficult to reliably...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Clin Chim Acta
Autori principali: Eveillard, Marion, Korde, Neha, Ciardiello, Amanda, Diamond, Benjamin, Lesokhin, Alexander, Mailankody, Sham, Smith, Eric, Hassoun, Hani, Hultcrantz, Malin, Shah, Urvi, Lu, Sydney, Salcedo, Meghan, Werner, Kelly, Rispoli, Jenna, Mastey, Donna, Landgren, Ola, Thoren, Katie
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2021
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7994191/
https://ncbi.nlm.nih.gov/pubmed/33545108
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.cca.2021.01.021
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi